JNJ vs PG
JNJ: Johnson & Johnson is a global leader in innovative pharmaceuticals and advanced medical technology dedicated to addressing the world's most complex health challenges. PG: A consumer staples giant with a diversified portfolio of household-name brands spanning beauty, health, and home care.
Side-by-side fundamentals
| Metric | JNJ | PG | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $265.95 | $148.63 | |
| Market cap as of 2026-07-30 | $646.5B | $346.1B | |
| P/E as of 2026-07-30 | 30.73 | 20.34 | PG lower |
| PEG as of 2026-07-30 | 3.16 | 6.94 | JNJ lower |
| Net margin as of 2026-07-30 | +21.5% | +19.2% | JNJ higher |
| Gross margin as of 2026-07-30 | +68.0% | +50.9% | JNJ higher |
| Operating margin as of 2026-07-30 | +25.7% | +23.6% | JNJ higher |
| ROE as of 2026-07-30 | +25.7% | +31.2% | PG higher |
| ROA as of 2026-07-30 | +10.6% | +13.1% | PG higher |
| Debt / equity as of 2026-07-30 | 0.58 | 0.68 | JNJ lower |
| Revenue growth (YoY) as of 2026-07-30 | +8.1% | +3.3% | JNJ higher |
| Revenue CAGR (3y) SEC XBRL | +6.2% | +1.7% | JNJ higher |
| Dividend yield as of 2026-07-30 | +2.0% | +2.9% | PG higher |
| Dividend streak (yrs) SEC XBRL | 5 | 3 | JNJ higher |
| Beta as of 2026-07-30 | 0.22 | 0.38 | |
| 1-year return as of 2026-07-27 close | +58.0% | -6.1% | JNJ higher |
Fundamentals: market data, as of 2026-07-30. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.